Home / Events / Future Events / INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEALTHCARE MEETING, JANUARY 10-13, 2022

INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEAL...

Houston, Texas, USA, Dec. 16, 2021 (GLOBE NEWSWIRE) — Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the 2022 edition of the JP Morgan Healthcare Meeting, held online on January 10-13, 2022.

In addition to the main meeting, Dr. Tyle will also attend Biotech ShowcaseTM, held virtually from January 10-19. He will present an overview of all of Invectys’ projects to date on January 11th, at 9:15 am Pacific time. The presentation has already been posted on the Biotech Showcase website.

If you would like to set up a meeting, feel free to contact us at contactus@invectys.com.

About Invectys

Invectys, Inc. is a clinical stage immuno-oncology company spun-out of the world renown Pasteur Institute, Paris. Invectys has two wholly owned subsidiaries, Invectys, S.A. (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston) which is dedicated to the development of the CPRIT initiative. Since 2010, Invectys has raised over $58 million in private funds to develop two innovative platforms of immunotherapy products which target “universal” tumor antigens.

Contact:
Invectys, Inc. – Rosie Williams
contactus@invectys.com